PsiQuantum Partners with Japan’s National Cancer Center on Quantum Oncology Research

PsiQuantum has announced a new collaborative research agreement with National Cancer Center Japan aimed at advancing the use of utility-scale quantum computing in oncology and healthcare. The partnership is expected to explore how next-generation quantum technologies could transform cancer research, pharmaceutical development, and healthcare resource management.

The collaboration will focus on developing applications that leverage large-scale quantum computing systems to improve outcomes across the cancer care ecosystem. By combining PsiQuantum’s quantum computing expertise with the National Cancer Center Japan’s clinical and research capabilities, the two organizations aim to identify innovative solutions for some of the most complex challenges in oncology.

As part of the agreement, the teams will work together to advance fault-tolerant quantum algorithms that could support clinically relevant applications. The initiative will also include collaboration with leading pharmaceutical companies in Japan to explore how quantum technologies may be integrated into real-world drug discovery and development workflows.

The research will utilize PsiQuantum’s proprietary software platform, Construct, which is designed as a secure end-to-end system for building, analyzing, and optimizing algorithms for fault-tolerant quantum computers. The platform allows researchers to experiment with advanced computational models that could help simulate complex biological and molecular interactions with far greater precision than traditional computing approaches.

According to Sam Pallister, Vice President for Quantum Applications at PsiQuantum, the collaboration represents a significant step toward realizing the potential of utility-scale quantum computing in healthcare. He emphasized that once large-scale quantum computers become operational, they could dramatically accelerate research and development processes and reshape the way new medicines are designed and brought to market.

Dr. Takayuki Yoshino, Director of the Department of Global Oncology at the National Cancer Center Hospital East in Kashiwa, Japan, said the partnership brings together expertise from multiple disciplines to tackle pressing healthcare challenges. He noted that the collaboration is expected to drive innovative research at the intersection of pharmaceuticals, biotechnology, and quantum computing.

Currently, the development of new pharmaceutical treatments is both time-consuming and costly, often taking years of research and billions of dollars in investment. Traditional computing systems frequently struggle to model the complex molecular structures involved in drug discovery, limiting their ability to accelerate breakthroughs.

Utility-scale quantum computers could significantly change this landscape. By enabling highly accurate simulations of molecular systems at unprecedented speed and scale, quantum technologies have the potential to shorten drug development timelines, reduce research costs, and improve the efficiency of healthcare innovation.

Through their new partnership, PsiQuantum and the National Cancer Center Japan aim to explore these possibilities and pave the way for quantum-enabled advances in cancer research and treatment.